Drug Discovery

Through our drug discovery platforms, we identify and develop new product candidates for significant unmet medical needs

Our drug discovery platforms are focused on small molecules and biologics and support the growth of our clinical pipeline.  We leverage our team of scientific experts and our advanced understanding of the molecular mechanisms of disease to establish development paths for disease areas where significant unmet medical needs exist.

In April 2015, we transferred our gene therapy platform to a subsidiary of MeiraGTx Holdings plc (NASDAQ: MGTX), an independent clinical-stage company in which Kadmon retains a meaningful interest.

Small Molecules

ROCK Inhibitors

Kadmon has identified and developed a portfolio of proprietary, next-generation inhibitors of Rho-associated coiled-coil kinase (ROCK), an “on” switch in cells that regulates cell movement, shape and differentiation.  Two ROCK isoforms exist: ROCK1 and ROCK2, and dysregulation of ROCK-driven cellular functions is implicated in many chronic diseases.   Kadmon research has helped define the role of ROCK in autoimmune, inflammatory and fibrotic diseases.

Kadmon’s ROCK inhibitor platform includes an oral, selectiveROCK2 inhibitor, KD025, in clinical development for autoimmune and inflammatory diseases, and a pan-ROCK (ROCK1/2) inhibitor, KD045, for the treatment of fibrotic diseases, for which IND-enabling studies are ongoing.


Kadmon’s fully human monoclonal antibody platform is run by an experienced team of scientists who have developed commercially successful antibodies prior to joining Kadmon, including Erbitux® (cetuximab) and Cyramza® (ramucirumab). We are developing monoclonal antibodies as well as fusion proteins that we believe represent the next generation of cancer therapeutics.

Our most advanced candidate from our biologics platform, KD033, is an anti-PD-L1/IL-15 fusion protein designed to stimulate an immune response directed to the tumor microenvironment. Recombinant IL-15 alone, which stimulates cancer-fighting immune effector cells, is not well tolerated when administered systemically. We have developed a novel approach to overcome this challenge by fusing IL-15 to an anti-PD-L1 antibody to direct IL-15 activity specifically to the tumor microenvironment, potentially promoting efficacy and inducing durable responses while increasing tolerability. We expect to complete an IND submission in the fourth quarter of 2019 and initiate a clinical trial of KD033 in the first half of 2020.